Research programme:GBA1 based gene therapies - Spur Therapeutics
Latest Information Update: 05 Jul 2024
At a glance
- Originator Spur Therapeutics
- Class Antiparkinsonians; Gene therapies
- Mechanism of Action Gene transference; Glucosylceramidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Parkinson's disease